A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
Public ClinicalTrials.gov record NCT04349072. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy
Study identification
- NCT ID
- NCT04349072
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 112 participants
Conditions and interventions
Interventions
- Mavacamten Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 5, 2020
- Primary completion
- Feb 6, 2022
- Completion
- May 19, 2024
- Last update posted
- May 22, 2025
2020 – 2024
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0009 | Los Angeles | California | 90027 | — |
| Local Institution - 0011 | Stanford | California | 94305 5406 | — |
| Local Institution - 0001 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0021 | Weston | Florida | 33331 | — |
| Local Institution - 0016 | Boston | Massachusetts | 02114-2696 | — |
| Local Institution - 0007 | Boston | Massachusetts | 02115 | — |
| Local Institution - 0006 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0013 | Grand Rapids | Michigan | 49503 | — |
| Local Institution - 0015 | Rochester | Minnesota | 55905 | — |
| Local Institution - 0005 | St Louis | Missouri | 63110 | — |
| Local Institution - 0010 | New York | New York | 10016 | — |
| Local Institution - 0017 | Valhalla | New York | 10595 | — |
| Local Institution - 0004 | Durham | North Carolina | 27710 | — |
| Local Institution - 0020 | Cleveland | Ohio | 44195 | — |
| Local Institution - 0002 | Portland | Oregon | 97239 | — |
| Local Institution - 0003 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0019 | Pittsburgh | Pennsylvania | 15212 | — |
| Local Institution - 0014 | Nashville | Tennessee | 37205 | — |
| Local Institution - 0018 | Nashville | Tennessee | 37235 | — |
| Local Institution | Houston | Texas | 77030 | — |
| Local Institution - 0012 | Murray | Utah | 84107-5701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04349072, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04349072 live on ClinicalTrials.gov.